The Value of Perioperative Chemotherapy for Patients With Hepatoid Adenocarcinoma of the Stomach Undergoing Radical Gastrectomy

Zhou, Kai; Wang, Anqiang; Wei, Jingtao; Ji, Ke; Li, Zhongwu; Ji, Xin; Fu, Tao; Jia, Ziyu; Wu, Xiaojiang; Zhang, Ji; Bu, Zhaode

doi:10.3389/fonc.2021.789104

Cited by 7 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GHA and GA share similar clinical symptoms and imaging findings ( 16 , 17 ). However, GHA always exhibits early lymphatic and hepatic metastases and is associated with a poorer prognosis than GA ( 11 ). Elevated AFP is observed in most patients with GHA, but normal AFP levels have also been reported ( 21 ).…”

Section: Discussionmentioning

confidence: 99%

“…Clinically, GHA mostly occurs in elderly male individuals without specific clinical characteristics and imaging findings ( 11 , 15 ). The average age of patients with GHA is 62.45 years, ranging from 56 to 74 years ( 17 ).…”

Section: Discussionmentioning

confidence: 99%

“…Gastric hepatoid adenocarcinoma (GHA) is histologically characterized by hepatoid differentiation and the production of large amounts of alpha-fetoprotein (AFP) ( 10 ). GHA always exhibits early lymphatic and hepatic metastases and is associated with a poor prognosis compared with gastric adenocarcinoma (GA) ( 11 ). According to current research, the management strategy for GHA is similar to that for GA ( 12 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Differential diagnostic value of tumor markers and contrast-enhanced computed tomography in gastric hepatoid adenocarcinoma and gastric adenocarcinoma

Dong

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThis study aimed to investigate the effectiveness of tumor markers and contrast-enhanced computed tomography (CE-CT) in differentiating gastric hepatoid adenocarcinoma (GHA) from gastric adenocarcinoma (GA).MethodsThis retrospective study included 160 patients (44 with GHA vs. 116 with GA) who underwent preoperative CE-CT. Preoperative serum concentrations of tumor biomarkers and CT imaging features were analyzed, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 125 (CA125), tumor location, growth pattern, size, enhancement pattern, cystic changes, and mass contrast enhancement. Multivariate logistic regression analyses were performed to evaluate useful tumor markers and CT imaging features for differentiating GHA from GA.ResultsWhen compared to GA, GHA showed a higher serum AFP [13.27 ng/ml (5.2–340.1) vs. 2.7 ng/ml (2.2–3.98), P <0.001] and CEA levels [4.07 ng/ml (2.73–12.53) vs. 2.42 ng/ml (1.38–4.31), P <0.001]. CT imaging showed GHA with a higher frequency of tumor location in the gastric antrum (P <0.001). GHA had significantly lower attenuation values at the portal venous phase [PCA, (82.34 HU ± 8.46 vs. 91.02 HU ± 10.62, P <0.001)] and delayed phase [DCA, (72.89 HU ± 8.83 vs. 78.27 HU ± 9.51, P <0.001)] when compared with GA. Multivariate logistic regression analyses revealed that tumor location, PCA, and serum AFP level were independent predictors of differentiation between GHA and GA. The combination of these three predictors performed well in discriminating GHA from GA, with an AUC of 0.903, a sensitivity of 86.36%, and a specificity of 81.90%.ConclusionsIntegrated evaluation of tumor markers and CT features, including tumor location, PCA, and serum AFP, allowed for more accurate differentiation of GHA from GA.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Differential diagnostic value of tumor markers and contrast-enhanced computed tomography in gastric hepatoid adenocarcinoma and gastric adenocarcinoma

Dong

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Except for MSI and EBV, other biomarker-positive gastric cancer patients also showed a response pattern to NAC. After propensity score matching, a retrospective study found no improvement in the survival of patients with stomach cancer and hepatoid adenocarcinoma [ 55 ]. In addition, patients with positive MET had significantly shorter PFS and OS than those with other gastric cancers who received NAC [ 56 ].…”

Section: Predictors Of Nac Outcomes In Gastric Cancermentioning

confidence: 99%

Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer

2023

View full text Add to dashboard Cite

Presently, surgery is the only treatment approach for gastric cancer and improving the prognosis of locally advanced gastric cancer is one of the key factors in promoting gastric cancer survival benefit. The MAGIC study was the first to demonstrate the efficacy of neoadjuvant chemotherapy (NAC) in European countries. In recent years, several clinical trials have provided evidence for the use of NAC in Asian patients with locally advanced gastric cancer. However, clinical practice guidelines vary between Asian and non-Asian populations. Optimal NAC regimens, proper target populations, and predictors of NAC outcomes in Asian patients are still under investigation. Herein, we summarized the current progress in the administration of NAC in Asian patients with gastric cancer.

show abstract

“…In general, the therapeutic effectiveness of anti‐HER2 and anti‐PD‐1 treatment is closely related to the amplification status of HER2 and combined positive score (CPS) for programmed death‐ligand 1 (PD‐L1) in the field of gastric cancer [ 14 , 15 ]. In previous studies, the HER2 positive rate determined by IHC ranged from 14.3% to 60% [ 3 , 12 , 13 , 16 , 17 ]. However, this rate was not usually validated by fluorescence in situ hybridization (FISH).…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases

Yang,

Wu,

Wang

et al. 2023

The Journal of Pathology CR

Self Cite

View full text Add to dashboard Cite

Hepatoid adenocarcinoma of stomach (HAS) is a special subtype of gastric cancer with poor prognosis. Immunohistochemical analysis could provide important clues for the treatment of HAS. A total of 159 patients were diagnosed as HAS and 139 were enrolled in this study. Statistical differences were determined using relative test methods and survival analyses were performed by the Kaplan–Meier method to find survival differences. All tumors in this study were negative for Epstein–Barr virus‐encoded small RNAs (EBERs) and almost all showed no loss of mismatch repair (MMR) proteins and were positive for alpha fetoprotein (AFP or spalt like transcription factor 4 (SALL4). About half of the tumors had a positive programmed death‐ligand 1 combined positive score (CPS) and 17.3% were positive for human epidermal growth factor receptor 2 (HER2). In addition, there was a relatively high proportion of cmet expression. We also found that HAS patients with recurrent disease treated by emerging therapy had a better survival than those treated with traditional chemotherapy (p = 0.002, median recurrence‐to‐death survival: 23 months versus 6 months); HAS patients who received anti‐HER2 therapy or harbored MMR deficiency had favorable prognosis. Overall, high proportions of MMR protein proficiency, positivity for AFP or SALL4, overexpression of HER2, CPS and cmet, as well as negative EBER findings, are distinctive characteristics of HAS patients. While negative EBER and MMR proficiency indicate molecular features of HAS, positivity for AFP or SALL4 could aid in the diagnosis of HAS. In addition, HAS patients could benefit from anti‐HER2 therapy, immunotherapy, and anti‐angiogenesis therapy.

show abstract

The Value of Perioperative Chemotherapy for Patients With Hepatoid Adenocarcinoma of the Stomach Undergoing Radical Gastrectomy

Cited by 7 publications

References 30 publications

Differential diagnostic value of tumor markers and contrast-enhanced computed tomography in gastric hepatoid adenocarcinoma and gastric adenocarcinoma

Differential diagnostic value of tumor markers and contrast-enhanced computed tomography in gastric hepatoid adenocarcinoma and gastric adenocarcinoma

Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer

Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases

Contact Info

Product

Resources

About